Medicament carrier for dry powder inhalator

• US 5,647,347 A
• Filed: 10/21/1994
• Issued: 07/15/1997
• Est. Priority Date: 10/21/1994
• Status: Expired due to Term

• Current Assignee: Glaxo Wellcome Incorporated (GSK plc)
• Original Assignee: Glaxo Wellcome Incorporated (GSK plc)
• Inventors: Van Oort, Michiel M.
• Primary Examiner(s): Millin, V.
• Assistant Examiner(s): Deane, Jr., William J.
• Application Number:
  US08/328,578
• Time in Patent Office: 998 Days
• Field of Search: 128/203.15, 128/203.19, 128/203.21, 128/203.23, 128/200.23
• US Class Current: 128/203.15
• CPC Class Codes: A61M 15/0045 using multiple prepacked dosages on a same carrier, e.g. blisters
• CPC Class Codes: A61M 15/0048 the dosages being arranged in a plane, e.g. on diskettes
• CPC Class Codes: A61M 15/005 the dosages being arranged on a cylindrical surface
• CPC Class Codes: A61M 15/0051 the dosages being arranged on a tape, e.g. strips
• CPC Class Codes: A61M 2202/064 Powder

Abstract

A medicament carrier for use in a dry powder inhalator device wherein the medicament carrier has at least one carrier screen portion. The carrier screen portion defines a plurality of interstices therein and carries a powdered medicament which is loaded onto the carrier screen portion surface such that the interstices of the carrier screen portion at least partially open and free of the dry powdered medicament.

Claims

1. A medicament carrier for use in a dry powder inhalator device comprising a carrier having at least one carrier screen portion defining a plurality of interstices therein and loaded with at least one dose of powdered medicament particles of predetermined particulate size, wherein the powdered medicament particles are loaded onto the carrier screen portion surface from a suspension of the medicament particles and suspending agent and the suspending agent is evaporated such that the interstices of the carrier screen portion surface are at least partially open and free of the powdered medicament particles.

2. The medicament carrier according to claim 1, wherein said screen portion is formed from a material selected from the group consisting of non-woven screens, woven screens, stamped metal blanks, photoacid etched stainless steel, and photoacid etched ceramic.

3. The medicament carrier according to claim 1, wherein said carrier comprises a plurality of carrier screen portions each loaded with one dose of the powdered medicament particles.

4. The medicament carrier according to claim 1, wherein the interstices in said carrier screen mesh portion are at least 0.0005 inches in width.

5. The medicament carrier according to claim 1, wherein the powdered medicament particles loaded on said carrier screen portion are selected from the group consisting of albuterol, terbutaline, isoproterenol, metaprotaranol, pirbuterol, salmeterol hydroxynapthoate, fluticasone propionate, budesonide, beclomethasone dipropionate, and triacetonide.

6. The medicament carrier according to claim 1, wherein at least one screen is positioned adjacent but spaced apart from said carrier to facilitate deaggregation of the powdered medicament particles.

7. The medicament carrier according to claim 6, wherein said at least one screen comprises two screens with one screen positioned adjacent but spaced apart from each side of said carrier to facilitate deaggregation of the powdered medicament particles.

8. A medicament carrier for use in a dry powder inhalator device comprising a carrier having at least one carrier portion comprising two spaced apart screens wherein each defines a plurality of substantially spherical substrate elements positioned between said screens and loaded with at least one dose of powdered medicament particles of predetermined particulate size from a suspension of the medicament particles and suspending agent and the suspending agent is evaporated, wherein the powdered medicament particles are removed from the spherical substrate elements and entrained in an air flow introduced through the two spaced apart screens.

9. The medicament carrier according to claim 8, wherein the surface of said plurality of spherical substrate elements is loaded with one dose of powdered medicament particles.

10. The medicament carrier according to claim 8, wherein the powdered medicament loaded onto said spherical substrate elements is selected from the group consisting of albuterol, terbutaline, isoproterenol, metaprotaranol, pirbuterol, salmeterol hydroxynapthoate, fluticasone propionate, budesonide, beclomethasone dipropionate, and triacetonide.